Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study

Charles B. Pratt, Alberto S. Pappo, Peter Gieser, Jesse J. Jenkins, Arnold Salzberg, James Neff, Bhaskar Rao, Dan Green, Patrick Thomas, Robert Marcus, David Parham, Harold Maurer

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Purpose: To prospectively study the value of adjuvant chemotherapy in pediatric patients with surgically resected nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS). Patients and Methods: From June 1986 to May 1992, after complete surgical resection (± radiotherapy) of their NRSTS, 81 eligible patients either received adjuvant chemotherapy comprising vincristine, dactinomycin, cyclophosphamide, and doxorubicin or were observed. Only 30 patients accepted randomization, and 15 were assigned to each regimen. Of the remaining 51 patients, 19 elected adjuvant chemotherapy and 32 elected observation. Results: Patients were predominantly male, and 69% of all patients were white. The median age at diagnosis was 12.3 years (range, 9.2 to 20.7 years). For the 81 eligible patients, the 5-year overall survival estimate was 84.5% ± 4.4% and event-free survival was 72.2% ± 5.4%. Among randomized patients, the 5-year estimated overall survival rate was 93.3% ± 7%, and the event-free survival rate was 86.7% ± 9.5% for the observation group, compared with 69.2% ± 13% and 40.7% ± 14%, respectively, for those who received chemotherapy. The significantly worse outcome of patients who received adjuvant chemotherapy disappeared when survival was stratified tumor grade. Among all patients, a grade 3 lesion conferred a significant disadvantage with respect to event-free survival (P = .0001). Conclusion: The administration of adjuvant chemotherapy according to the schedule and dosages used in our trial did not improve the outcome of children with resected NRSTS. In this study, tumor grade was the most important predictor of clinical outcome in patients with resected NRSTS, and this factor should be incorporated into the stratification of patients in future trials.

Original languageEnglish (US)
Pages (from-to)1219-1226
Number of pages8
JournalJournal of Clinical Oncology
Volume17
Issue number4
StatePublished - Apr 1 1999

Fingerprint

Adjuvant Chemotherapy
Sarcoma
Pediatrics
Therapeutics
Disease-Free Survival
Survival Rate
Observation
Survival
Thromboplastin
Dactinomycin
Vincristine
Random Allocation
Doxorubicin
Cyclophosphamide
Neoplasms
Appointments and Schedules
Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pratt, C. B., Pappo, A. S., Gieser, P., Jenkins, J. J., Salzberg, A., Neff, J., ... Maurer, H. (1999). Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study. Journal of Clinical Oncology, 17(4), 1219-1226.

Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas : A Pediatric Oncology Group Study. / Pratt, Charles B.; Pappo, Alberto S.; Gieser, Peter; Jenkins, Jesse J.; Salzberg, Arnold; Neff, James; Rao, Bhaskar; Green, Dan; Thomas, Patrick; Marcus, Robert; Parham, David; Maurer, Harold.

In: Journal of Clinical Oncology, Vol. 17, No. 4, 01.04.1999, p. 1219-1226.

Research output: Contribution to journalArticle

Pratt, CB, Pappo, AS, Gieser, P, Jenkins, JJ, Salzberg, A, Neff, J, Rao, B, Green, D, Thomas, P, Marcus, R, Parham, D & Maurer, H 1999, 'Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study', Journal of Clinical Oncology, vol. 17, no. 4, pp. 1219-1226.
Pratt, Charles B. ; Pappo, Alberto S. ; Gieser, Peter ; Jenkins, Jesse J. ; Salzberg, Arnold ; Neff, James ; Rao, Bhaskar ; Green, Dan ; Thomas, Patrick ; Marcus, Robert ; Parham, David ; Maurer, Harold. / Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas : A Pediatric Oncology Group Study. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 4. pp. 1219-1226.
@article{3e2756f24c6840aba4077de243f6a9cb,
title = "Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study",
abstract = "Purpose: To prospectively study the value of adjuvant chemotherapy in pediatric patients with surgically resected nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS). Patients and Methods: From June 1986 to May 1992, after complete surgical resection (± radiotherapy) of their NRSTS, 81 eligible patients either received adjuvant chemotherapy comprising vincristine, dactinomycin, cyclophosphamide, and doxorubicin or were observed. Only 30 patients accepted randomization, and 15 were assigned to each regimen. Of the remaining 51 patients, 19 elected adjuvant chemotherapy and 32 elected observation. Results: Patients were predominantly male, and 69{\%} of all patients were white. The median age at diagnosis was 12.3 years (range, 9.2 to 20.7 years). For the 81 eligible patients, the 5-year overall survival estimate was 84.5{\%} ± 4.4{\%} and event-free survival was 72.2{\%} ± 5.4{\%}. Among randomized patients, the 5-year estimated overall survival rate was 93.3{\%} ± 7{\%}, and the event-free survival rate was 86.7{\%} ± 9.5{\%} for the observation group, compared with 69.2{\%} ± 13{\%} and 40.7{\%} ± 14{\%}, respectively, for those who received chemotherapy. The significantly worse outcome of patients who received adjuvant chemotherapy disappeared when survival was stratified tumor grade. Among all patients, a grade 3 lesion conferred a significant disadvantage with respect to event-free survival (P = .0001). Conclusion: The administration of adjuvant chemotherapy according to the schedule and dosages used in our trial did not improve the outcome of children with resected NRSTS. In this study, tumor grade was the most important predictor of clinical outcome in patients with resected NRSTS, and this factor should be incorporated into the stratification of patients in future trials.",
author = "Pratt, {Charles B.} and Pappo, {Alberto S.} and Peter Gieser and Jenkins, {Jesse J.} and Arnold Salzberg and James Neff and Bhaskar Rao and Dan Green and Patrick Thomas and Robert Marcus and David Parham and Harold Maurer",
year = "1999",
month = "4",
day = "1",
language = "English (US)",
volume = "17",
pages = "1219--1226",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas

T2 - A Pediatric Oncology Group Study

AU - Pratt, Charles B.

AU - Pappo, Alberto S.

AU - Gieser, Peter

AU - Jenkins, Jesse J.

AU - Salzberg, Arnold

AU - Neff, James

AU - Rao, Bhaskar

AU - Green, Dan

AU - Thomas, Patrick

AU - Marcus, Robert

AU - Parham, David

AU - Maurer, Harold

PY - 1999/4/1

Y1 - 1999/4/1

N2 - Purpose: To prospectively study the value of adjuvant chemotherapy in pediatric patients with surgically resected nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS). Patients and Methods: From June 1986 to May 1992, after complete surgical resection (± radiotherapy) of their NRSTS, 81 eligible patients either received adjuvant chemotherapy comprising vincristine, dactinomycin, cyclophosphamide, and doxorubicin or were observed. Only 30 patients accepted randomization, and 15 were assigned to each regimen. Of the remaining 51 patients, 19 elected adjuvant chemotherapy and 32 elected observation. Results: Patients were predominantly male, and 69% of all patients were white. The median age at diagnosis was 12.3 years (range, 9.2 to 20.7 years). For the 81 eligible patients, the 5-year overall survival estimate was 84.5% ± 4.4% and event-free survival was 72.2% ± 5.4%. Among randomized patients, the 5-year estimated overall survival rate was 93.3% ± 7%, and the event-free survival rate was 86.7% ± 9.5% for the observation group, compared with 69.2% ± 13% and 40.7% ± 14%, respectively, for those who received chemotherapy. The significantly worse outcome of patients who received adjuvant chemotherapy disappeared when survival was stratified tumor grade. Among all patients, a grade 3 lesion conferred a significant disadvantage with respect to event-free survival (P = .0001). Conclusion: The administration of adjuvant chemotherapy according to the schedule and dosages used in our trial did not improve the outcome of children with resected NRSTS. In this study, tumor grade was the most important predictor of clinical outcome in patients with resected NRSTS, and this factor should be incorporated into the stratification of patients in future trials.

AB - Purpose: To prospectively study the value of adjuvant chemotherapy in pediatric patients with surgically resected nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS). Patients and Methods: From June 1986 to May 1992, after complete surgical resection (± radiotherapy) of their NRSTS, 81 eligible patients either received adjuvant chemotherapy comprising vincristine, dactinomycin, cyclophosphamide, and doxorubicin or were observed. Only 30 patients accepted randomization, and 15 were assigned to each regimen. Of the remaining 51 patients, 19 elected adjuvant chemotherapy and 32 elected observation. Results: Patients were predominantly male, and 69% of all patients were white. The median age at diagnosis was 12.3 years (range, 9.2 to 20.7 years). For the 81 eligible patients, the 5-year overall survival estimate was 84.5% ± 4.4% and event-free survival was 72.2% ± 5.4%. Among randomized patients, the 5-year estimated overall survival rate was 93.3% ± 7%, and the event-free survival rate was 86.7% ± 9.5% for the observation group, compared with 69.2% ± 13% and 40.7% ± 14%, respectively, for those who received chemotherapy. The significantly worse outcome of patients who received adjuvant chemotherapy disappeared when survival was stratified tumor grade. Among all patients, a grade 3 lesion conferred a significant disadvantage with respect to event-free survival (P = .0001). Conclusion: The administration of adjuvant chemotherapy according to the schedule and dosages used in our trial did not improve the outcome of children with resected NRSTS. In this study, tumor grade was the most important predictor of clinical outcome in patients with resected NRSTS, and this factor should be incorporated into the stratification of patients in future trials.

UR - http://www.scopus.com/inward/record.url?scp=0032927813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032927813&partnerID=8YFLogxK

M3 - Article

C2 - 10561182

AN - SCOPUS:0032927813

VL - 17

SP - 1219

EP - 1226

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -